Breast cancer is the leading cause of cancer in women in China. Preoperative chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Paclitaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Platinum complexes, like cisplatin and carboplatin, are active in a wide range of solid tumors. Paclitaxel combined with carboplatin has shown great activity in ovarian and nonsmall- cell lung cancer treatment. In addition, the overall response rate of paclitaxel plus carboplatin was between 53% and 62% in the first-line treatment of metastatic breast cancer. This study will evaluate the pCR rate of weekly paclitaxel plus carboplatin as preoperative treatment for breast cancer patients ...
In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the companys "String of Pearls" strategy of alliances, partnerships and acquisitions.[28] In November, Bristol-Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move was expected to further sharpen the companys focus on biopharmaceuticals. In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas. Bristol-Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce Hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitexs shareholders acceptance of 126 percent premium price of its price over the previous 20 trading days ended on ...
Disclosure of Interest T. W. J. Huizinga Grant/research support from: EU & Dutch Arthritis Foundation, Consultant for: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Crescendo Bioscience, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, UCB, Inc., Eli Lilly, Meteor Board, Speakers bureau: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, S. E. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, A. Johnsen Employee of: Bristol-Myers Squibb, J. Zhu Employee of: Bristol-Myers Squibb, D. E. Furst Grant/research support from: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Consultant for: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Speakers bureau: (CME only) AbbVie, Actelion, UCB, V. P. ...
Get information, facts, and pictures about Bristol-Myers Squibb Company at Encyclopedia.com. Make research projects and school reports about Bristol-Myers Squibb Company easy with credible articles from our FREE, online encyclopedia and dictionary.
PRIMARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior death rate when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. SECONDARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior progression-free survival when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. II. To determine if acute toxicity, specifically physician-assessed neurotoxicity and infection, associated with combination paclitaxel and carboplatin chemotherapy is reduced compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. III. To determine if treatment with combination paclitaxel and carboplatin chemotherapy is associated with superior patient-reported quality of life and neurotoxicity scores compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. TERTIARY OBJECTIVES:. I. To bank formalin-fixed, ...
TY - JOUR. T1 - Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. AU - Sudo, Tamotsu. AU - Nitta, Masayuki. AU - Saya, Hideyuki. AU - Ueno, Naoto T.. PY - 2004/4/1. Y1 - 2004/4/1. N2 - Paclitaxel stabilizes microtubules, causing mitotic arrest and activating the spindle assembly checkpoint. We determined whether suppression of the checkpoint genes Mad2 and BubR1 affects paclitaxel resistance and whether overexpression of Mad2 protein in checkpoint-defective cells enhances paclitaxel sensitivity. Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity. In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity. However, overexpression of ...
... NEW BRUNSWICK N.J. Nov. 30 /- Underscorin...The Bristol-Myers Squibb Pediatric Infectious Disease and ImmunologyC... At Bristol-Myers Squibb we believe that together we can prevail over...The new infectious disease and immunology center is the latest example...,Bristol-Myers,Squibb,,New,Jersey,Childrens,Hospital,Launch,Center,for,Immune,System,Disorders,&,Infectious,Diseases,Including,HIV/AIDS,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
BACKGROUND: Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity. METHODS: A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. All statistical tests were two-sided. RESULTS: Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control
OREANDA-NEWS. Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Validation of the application confirms the submission is complete and begins the EMAs centralized review process.. "The high frequency of metastatic urothelial carcinoma and its relapsing nature highlight the substantial need for new treatment approaches with high and durable responses," said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. "We look forward to working with the EMA to potentially extend the use of Opdivo and bring the science of Immuno-Oncology to help patients in Europe fight this difficult-to-treat, advanced form of bladder cancer.". The application primarily included data from ...
Author Disclosures: C.N. Hess: None. S. James: Research Grant; Significant; AstraZeneca. Other Research Support; Modest; The Medicines Company, Correvio, Sanofi. Consultant/Advisory Board; Modest; Sanofi. D.M. Wojdyla: None. R.D. Lopes: Research Grant; Significant; Bristol-Myers Squibb, GlaxoSmithKline. Consultant/Advisory Board; Modest; Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer. D. Liaw: Employment; Significant; Bristol-Myers Squibb. E. Hagstrom: Honoraria; Significant; Sanofi. D.L. Bhatt: Research Grant; Significant; Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, The Medicines Company. S. Husted: Research Grant; Significant; GlaxoSmithKline, Pfizer. Consultant/Advisory Board; Modest; Bayer, AstraZeneca, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim. S.G. Goodman: Research Grant; Significant; AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, Sanofi. Honoraria; ...
mmuno-Oncology (I-O), and the research behind it, aspires to beat cancer at its own game. In February 2017, it was named advance of the year for a second year in a row by the American Society of Clinical Oncology (ASCO). "The sheer amount of translational research underway with groundbreaking I-O approaches is very exciting," says Steven Averbuch, vice president, Translational Clinical Development & Pharmacodiagnostics at Bristol-Myers Squibb.. But despite the progress to date, less than 50 percent of patients respond to I-O, depending on the patient population and the specific types of cancers involved. A stat like that begs the question: Why do some people respond to immunotherapies while others dont?. Building on knowledge gleaned from nearly 20 years of researching immunotherapies, Bristol-Myers Squibb scientists are hunting for answers to that question at an accelerated pace with the help of cutting-edge technologies. They are investigating the biology of cancer and the immune system at ...
Using NOVO-DENTOCAINE LIQ 65MG/ML during pregnancy may raise the risk of children developing some disorder (commpon for some such kind of drugs), however it depends upon how NOVO-DENTOCAINE LIQ 65MG/ML ingredients pass through placenta and may have effect on baby - Strength of NOVO-DENTOCAINE LIQ 65MG/ML is major factor in determination of such side effects, The possible danger in pregnancy are under research. BRISTOL-MYERS SQUIBB, S.A Canada publish leaflet about NOVO-DENTOCAINE LIQ 65MG/ML every update to describe possible risks of using NOVO-DENTOCAINE LIQ 65MG/ML side effect in pregnancy and pregnant women. You may download BRISTOL-MYERS SQUIBB, S.A issued leaflet regarding side effects of NOVO-DENTOCAINE LIQ 65MG/ML - BENZOCAINE. Pregnancy Side Effects can be easily know by Atc code of NOVO-DENTOCAINE LIQ 65MG/ML ATC CODE.. ...
Faculty Disclosure. Dr Kane has been a consultant for Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has received honoraria from Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has been on the speakers/advisory boards for Bristol-Myers Squibb, Genentech, and Otsuka; and has been a stock shareholder in MedAvante.. Dr Correll has been a consultant for Bristol-Myers Squibb, Eli Lilly, Gerson Lehrman Group, Intra-Cellular Therapies, Lundbeck, MedAvante, Pfizer, ProPhase, Otsuka, Sunovion, and Vanda; has received grant/research support from Bristol-Myers Squibb, Janssen, Johnson & Johnson, Novo Nordisk A/S, and Otsuka; has received honoraria from Medscape; has been on the speaker/advisory boards of Alexza, Bristol-Myers Squibb, Eli Lilly, Genentech, Intra-Cellular Therapies, Lundbeck, Merck, ...
CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement. Bristol-Myers Squibb is committed to the discovery and development of
In this study, evidence has been collected that supports the notion that paclitaxel may exert its toxicity via elevation of intracellular O2−, H2O2, and NO levels. This theory is confirmed by our data showing that (a) paclitaxel induced the production of O2−, H2O2 and NO; (b) paclitaxel induced oxidative DNA damage; (c) agents that decreased H2O2 and NO production suppressed paclitaxel-induced DNA damage, G2-M arrest, apoptosis, and cell growth inhibition; (d) inhibition of SOD or glutamylcysteine synthase increased paclitaxel-induced apoptosis; (e) cell lines with higher total antioxidant capacity were more resistant to paclitaxel cytotoxicity; and (f) agents that decreased clonogenic survival in paclitaxel-treated cells also decreased cellular total antioxidant capacity. Thus, paclitaxel chemoresistance correlates very well to intracellular antioxidant capacity.. Kong et al. ( 27) speculated that many chemotherapeutic agents exert their toxic effects on cancer cells by producing free ...
Disclosure of Interest R. Alten Grant/research support from: BMS, Merck Pharma GmbH, Wyeth Pharmaceuticals, Pfizer, Consultant for: Abbott Laboratories, Horizon Pharma, Merck Pharma GmbH, Nitec Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, Speakers bureau: Abbott Laboratories, BMS, Horizon Pharma, Merck Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, M. Hochberg Grant/research support from: NIH, Consultant for: Abbott Laboratories, Amgen Inc., BMS, Eli Lilly and Company, EMD Serono Inc., Genentech/Roche, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc, Speakers bureau: Bioberica SA, IBSA, Rottapharm/Madaus, R. Cohen Consultant for: Bristol-Myers Squibb, M. Weinblatt Grant/research support from: Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Abbott, J. Kaine Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, UCB, E. Keystone Grant/research support from: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP;, ...
TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...
FDA Approves Sanofi-Aventis and Bristol-Myers Squibb New 300mg Loading Dose Tablet for PLAVIX BRIDGEWATER and PRINCETON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Sanofi-aventis and Bristol-Myers
April 5, 2013. -Two Phase 2 studies to evaluate once-daily combination of Vertexs investigational nucleotide analogue VX-135 and BMS investigational NS5A replication complex inhibitor daclatasvir-. -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-. -Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013-. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYSE: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertexs nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibbs NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in ...
LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1
Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
Grant Support: By the National Heart, Lung, and Blood Institute (contract N01-HC-35130). The ALLHAT investigators received study medications from Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support from Pfizer.. Potential Financial Conflicts of Interest:Consultancies: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed); Honoraria: B.R. Davis (Pfizer), J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed), P. Whelton (Pfizer); Grants received: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Eli Lilly & Co., Merck & Co., Novartis Pharma AG, Pfizer, Searle & Co., SmithKline Beecham, Solvay/Unimed); J.A. Cutler (Pfizer, AstraZeneca, Bristol-Myers ...
TY - JOUR. T1 - Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. AU - Nguyen, Dao M.. AU - Chen, G. Aaron. AU - Reddy, Rishindra. AU - Tsai, Wilson. AU - Schrump, William D.. AU - Cole, George. AU - Schrump, David S.. AU - Jones, David A.. AU - Mentzer, Steven J.. AU - Harpole, David H.. PY - 2004/2. Y1 - 2004/2. N2 - Background: Constitutive activation of the phosphoinositide 3-kinase/protein kinase B survival signal transduction pathway influences the intrinsic chemoresistance of cancer cells. This study evaluates the effect of LY294002, a pharmacologic inhibitor of phosphoinositide 3-kinase, on the sensitivity of lung and esophageal cancer cells to paclitaxel (Taxol) in vitro. Materials and Methods: Cell viability and apoptosis of cancer cells treated with paclitaxel + LY294002 combinations were quantitated by methyl-thiazol-diphenyl-tetrazolium and ...
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
Were midway through the week and things have already been moving pretty fast. Action across the biotechnology sector is dictated by a variety of inputs but development stage pipeline updates are where the real action lies and - as we head into the bell on Wednesday - there are a couple of key pipeline related events that are going to set sentiment for the day. Heres a look at which companies are moving, whats moving each and whats next for the companies in question.. The two companies in focus for the session today are Bristol-Myers Squibb Company (NYSE:BMY) and Portola Pharmaceuticals Inc. (NASDAQ:PTLA).. First up, then, BMS.. After the closing bell rang on Tuesday, BMS announced top line data from a study called CheckMate-214. The trial was set up to investigate the potential use of Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as compared to an already approved (and pretty well established) standard of care drug called sunitinib. The target indication in this instance was ...
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. Additionally, our philanthropic programs have given new hope to some of the worlds most vulnerable communities and the preservation of our natural resources represents one of our key commitments. Our BioPharma strategy uniquely combines the best elements of a traditional pharmaceutical company with the entrepreneurial spirit and agility of a leading-edge biotech company - and our strategy is working. Since 2002, we have delivered 13 key new products to patients with serious diseases, four of these medicines are biologic products, and our pipeline continues to deliver. In 2011, we received approvals ...
FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3. http://news.bms.com/press-release/fda-approves-daklinza-daclatasvir-treatment-patients-chronic-hepatitis-c-genotype-3, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Financial Help Info for Daklinza (daclatasvir) . http://www.daklinza.bmscustomerconnect.com/support, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Highlights of Prescribing Information - DAKLINZA. http://packageinserts.bms.com/pi/pi_daklinza.pdf, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Patient Support Connect. http://www.patientsupportconnect.bmscustomerconnect.com/, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. ...
Home » Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicines Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy ...
This Boston Biotech Just Got Scooped Up for $300M By Bristol-Myers Squibb - read this article along with other careers information, tips and advice on BioSpace
Product Details :: Buy Plavix by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, British Dispensary, Bayer, Lilly: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com
Product Details :: Buy Bespar by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, Balkan Pharmaceuticals, Flonase, Casablanca Pharmaceuticals: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough
Source: S&P Capital IQ. TTM = trailing 12 months.. Unfortunately, that table doesnt tell us much about where Bristol-Myers Squibb has been, or where its going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it cant make up for this problem by cutting costs -- and most companies cant -- then both the business and its shares face a decidedly bleak outlook.. Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a companys profitability. Thats why I like to look at five fiscal years worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter. You cant always reach a hard ...
Multilind Suspension information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Multilind Suspension indications, usages and related health products lists
Explore comprehensive information about Bristol-Myers Squibb products including dosage and safety information. Learn more about our medicines today.
Balnetar information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Balnetar indications, usages and related health products lists
American pharmaceutical giant Bristol-Myers Squibb is set to buy US biotech company Inhibitex in a $2.5bn (£1.6bn) deal, bolstering its portfolio of drugs targeting the burgeoning hepatitis C market.
Former Bristol-Myers Squibb executive Robert Ramnarine of East Brunswick, N.J., pleaded guilty Monday in federal court in Trenton to charges that he got rich by using advance knowledge of the companys pending acquisition on Amylin in 2012. - David Sell, Philadelphia Inquirer
Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the
Drug firm, subsidiary settle suits for $515m Pricing schemes, fraud alleged By Jonathan Saltzman and Liz Kowalczyk, Globe Staff | September 29, 2007 Bristol-Myers Squibb and a subsidiary...
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2013....BMY
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance...
Paclitaxel best suppliers; Paclitaxel best sources; Paclitaxel best vendors; Paclitaxel protocol; Paclitaxel citations; Paclitaxel publications; Paclitaxel papers - Labshake
Endothelial cell migration is a critical event during angiogenesis, and inhibitors of cell motility can affect the angiogenic process. Paclitaxel (Taxol(R)), a microtubule-stabilizing antineoplastic cytotoxic drug, inhibits motility and invasiveness of several cell types. The aim of this study was to investigate the effect of paclitaxel on endothelial cell functions and on angiogenesis. In vivo, paclitaxel (20-28 mg/kg i.v.) significantly inhibited the angiogenic response induced by tumor cell supernatant embedded in a pellet of reconstituted basement membrane (Matrigel) injected s.c. into C57BL/6N mice. In vitro, paclitaxel inhibited endothelial cell proliferation, motility, invasiveness, and cord formation on Matrigel in a dose-dependent manner. The antiangiogenic activity of paclitaxel was not linked to its cytotoxicity, since inhibition of endothelial cell chemotaxis and invasiveness occurred at drug concentrations which did not affect endothelial cell proliferation. Another cytotoxic drug, ...
The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel. We studied 93 Caucasian women with ovarian cancer treated with paclitaxel and carboplatin. Using sparse sampling and nonlinear mixed effects modeling, the individual clearance of unbound paclitaxel was estimated from total plasma paclitaxel and Cremophor EL. The geometric mean of clearance was 385 l h(-1) (range 176-726 l h(-1)). Carriers of CYP2C8*3 had 11% lower clearance than non-carriers, P = 0.03. This has not been shown before in similar studies; the explanation is probably the advantage of using both unbound paclitaxel clearance and a population of patients of same gender. No significant association was found for the ABCB1 variants C1236T, G2677T/A and C3435T. Secondarily, other candidate single-nucleotide polymorphisms were explored with possible associations found for CYP2C8*4 (P = 0.04) and ABCC1 g.7356253C andgt; G (P = 0.04).. ...
TY - JOUR. T1 - Paclitaxel (Taxol). T2 - An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. AU - Lau, Derick H. AU - Xue, Ling. AU - Young, Lawrence J.. AU - Burke, Patricia A.. AU - Cheung, Anthony T.. PY - 1999. Y1 - 1999. N2 - Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed ...
This small phase II study provides a direct comparison between cisplatin and paclitaxel used as weekly concurrent chemotherapy with definitive radiation for advanced carcinoma of the cervix. Our data indicate that the overall response and progression free survival rates with the use of paclitaxel, which is the experimental arm, are not superior to those with cisplatin. In fact, there were non-significant trends for a higher relapse rate, higher gastrointestinal toxicity, and more allergic reactions in the concurrent paclitaxel group. Taken together, these results indicate that paclitaxel does not provide any clinical advantage over the current standard of concurrent cisplatin in CTRT for patients with advanced cervical carcinoma.. Although many prospective studies had shown that CTRT with cisplatin-based chemotherapy clearly improve the outcome of patients with carcinoma of the cervix, many patients treated on these protocols continue to fail in the pelvis and at distant sites [6, 16, 22, 23]. ...
Today, Biolyse Pharma is the industry leader in the research and development of injectable Paclitaxel products for use in cancer treatments.. Since Biolyse researchers first discovered that Paclitaxel could be produced from Taxus canadensis the company has gained fourteen years of valuable experience with the product. In September of 1994, Biolyse obtained authorization from the Federal Health Protection Branch (HPB) to administer its Paclitaxel for Injection, to patients under a clinical trial program.. Paclitaxel is a chemotherapeutic agent that is currently prescribed worldwide to treat the most aggressive forms of ovarian, lung and breast cancer, as well as AIDS related Kaposis sarcoma. Paclitaxel belongs to the chemical group known as taxanes, a family of molecules found in various natural sources. Paclitaxel is considered by the scientific and medical community as a first line of defense in the treatment of cancer. In 1992, both the American and Canadian National Cancer Institutes ...
Our results demonstrate an interaction between lovastatin and paclitaxel in several cellular processes. In both the K562 and HL-60 cell lines, lovastatin was found to enhance paclitaxel-induced cytotoxicity in a synergistic manner (Fig. 1 and 2). In addition, lovastatin enhanced paclitaxel-induced G2-M arrest in both cell lines and paclitaxel-induced apoptosis in the HL-60 cells (Fig. 3-5). These interactions were not attributable to an effect by lovastatin on cellular paclitaxel levels (Fig. 6) or to a general effect by paclitaxel on isoprenylated proteins (Fig. 7). However, we found evidence to suggest that alterations in the expression of the isoprenylated centromere-associated protein mitosin might be involved (Fig. 8 and 9).. Because of a report that indicated that paclitaxel could alter protein isoprenylation (26), we investigated the effects of lovastatin and/or paclitaxel treatment on several isoprenylated proteins. Importantly, we found no evidence to suggest that paclitaxel alters ...
As a single agent, paclitaxel has a response rate of 33% and 25-29% in SCLC patients with sensitive relapse and with resistant relapse, respectively. As